Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us

    News: Drug Discovery

    VUMC and Incyte Corp. form new scientific alliance

    Thursday, October 22nd, 2015

    Vanderbilt University Medical Center (VUMC) investigators have joined forces with scientists at Incyte Corp. to explore new therapies for the treatment of various types of cancer, as well as other diseases. The company has agreed to help fund basic and translational science research by VUMC investigators. Incyte Corp. is a Wilmington, Delaware-based biopharmaceutical company focused […]

    Collaboration seeks to develop new therapies for bone, other diseases

    Thursday, October 1st, 2015

    Drug discovery efforts that started in zebrafish are moving closer to clinical development. La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range […]

    Team to explore using nanoparticles to fight cancer

    Thursday, September 24th, 2015

    Three Vanderbilt researchers have received a federal grant to study the use of nanoparticles to deliver potential therapies for breast cancer that has spread to the bone. The grant from the Department of Defense Breast Cancer Research Program will provide more than $700,000 over three years in support of the research spearheaded by Julie Sterling, […]

    Drug combos enhance ovarian cancer cell death

    Monday, August 24th, 2015

    Ovarian cancer is often diagnosed at an advanced stage and frequently develops resistance to platinum chemotherapy. Identifying new drug combinations to overcome platinum resistance is a critical clinical challenge. They report in the Journal of Ovarian Research that combined thymoquinone and cisplatin had synergistic anti-tumor effects in cultured cells. The drug combination reduced tumor burden and […]

    Anticancer olive compounds

    Thursday, July 30th, 2015

    Natural compounds from plants – phytochemicals – provide a variety of health benefits, including anticancer activity. The human topoisomerases, enzymes that “detangle” DNA, are important targets for plant-derived anticancer drugs. To discover novel phytochemicals with anticancer activity, Kendra Vann, Neil Osheroff, Ph.D., and colleagues screened a library of 341 Mediterranean plant extracts for activity against […]

    Damon Runyon cancer grant boosts Davila’s research

    Thursday, July 23rd, 2015

    Marco Davila, M.D., Ph.D., assistant professor of Medicine and of Cancer Biology, has received a grant from the Damon Runyon Cancer Research Foundation that will provide $450,000 over three years to help fund his research on therapies for several types of blood disorders, including various forms of leukemia and non-Hodgkin (also known as non-Hodgkin’s) lymphoma. Davila’s […]

    Study reveals how protein helps cells tolerate DNA damage

    Thursday, July 16th, 2015

    Every day, cells in our bodies copy their DNA — about 6 billion “letters” worth — and divide. DNA replication is a fundamental process in biology, but it isn’t fully understood, said Brandt Eichman, Ph.D., associate professor of Biological Sciences and Biochemistry. And it doesn’t always proceed smoothly. DNA damage and other problems in the […]

    VICC, Incyte collaborate to study cancer therapies

    Thursday, July 9th, 2015

    Vanderbilt-Ingram Cancer Center (VICC) has entered into a multi-year research support and collaboration agreement with Incyte Corporation. The agreement will support basic and translational research to enable novel therapeutic approaches for patients with cancer. See press release.  

    Cancer signaling pathway blocker

    Friday, April 10th, 2015

    Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer. Abnormal regulation of this pathway leads to several human malignancies, including small cell lung cancer and pancreatic cancer, and therefore it is a potential drug target for cancer. Small molecules have […]

    Micelle “packets” deliver cancer drugs

    Friday, April 10th, 2015

    Small interfering RNA (siRNA) molecules can suppress tumor growth and target cells otherwise untreatable by conventional therapeutics, but targeted, intracellular delivery is a significant limitation to siRNA translation. To deliver the siRNA molecules into tumor cells, researchers have packaged them in micelles that express folic acid, which is internalized by cancer cells that overexpress folate […]

    Next Page »

    E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us